Difelene

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Difelene

Quick Facts

Property Description
Active ingredient Diclofenac (Sodium/Potassium Salt)
Form Tablets, Capsules, Gel, Injection, Suppositories
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Symptomatic relief of pain, inflammation, and fever
Origin Synthetic compound

What Type of Medicine is Difelene (Diclofenac)?

Difelene is a pharmaceutical preparation whose active substance is Diclofenac, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This medication is a synthetic compound belonging to the phenylacetic acid chemical family. Diclofenac is clinically recognized for its efficacy in targeting pain and inflammation compared to some other agents in its class.

This classification places Diclofenac within the major group of pain relievers, but its specific chemical structure offers a unique profile. Diclofenac achieves its therapeutic effects by hindering the synthesis of prostaglandins, which are mediators of pain and tissue swelling.

Composition and Available Preparations

The active component in Difelene is Diclofenac, often formulated as a sodium or potassium salt to optimize stability and absorption within the body. The compound itself is a monocarboxylic acid derivative.

The medication is available in a wide spectrum of dosage forms suited for different administration needs. These include specialized oral tablets (such as delayed-release and extended-release options), capsules, solutions for injection for rapid systemic action, and various topical forms, including gels and patches. The breadth of these preparations ensures flexible use, whether for localized joint discomfort or for a broader anti-inflammatory effect.

Primary Therapeutic Goal of the Active Ingredient

The general purpose of Diclofenac is to mitigate symptoms associated with inflammation and pain through its fundamental pharmacological actions. By limiting the production of these key inflammatory mediators, the compound delivers a powerful combined effect. This core function translates into three general benefits: providing effective analgesic (pain-relieving) properties, reducing tissue swelling and warmth through its anti-inflammatory action, and exerting an antipyretic (fever-reducing) effect. The primary goal is symptomatic management, positioning it as an established substance for relieving discomfort and controlling the biological responses linked to the inflammatory cascade.

What side effects are possible with Difelene?

Possible Side Effects and Safety Information: Difelene

Official regulatory information emphasizes that the use of Difelene carries the risk of serious side effects, which are documented across various body systems and classified by frequency.

Serious Safety Risks

Formal safety documents include prominent warnings regarding two major potential risks:

  • Cardiovascular Thrombotic Events: An increased risk of serious, and potentially fatal, events such as myocardial infarction (heart attack) and stroke has been documented. This risk may increase with duration of use and higher dosage.
  • Gastrointestinal Events: A serious warning exists for major gastrointestinal (GI) adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning symptoms.

Documented Adverse Reactions

Adverse reactions are officially categorized by System Organ Class (SOC) and frequency. Examples of documented reactions include:

Frequency Category Examples of Side Effects by System Organ Class
Common (affecting up to 1 in 10 people) Headache, dizziness, injection site reactions, rash.
Rare (affecting up to 1 in 1,000 people) Hypersensitivity and anaphylactic/anaphylactoid reactions, asthma.
Very Rare (affecting up to 1 in 10,000 people) Serious skin adverse reactions (e.g., Stevens-Johnson Syndrome), thrombocytopenia, acute renal failure, hepatitis.

Safety Restrictions and Contraindications

Difelene is contraindicated and must not be used in specific high-risk circumstances, as documented by regulatory authorities:

  • In the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Starting at the 30th week of pregnancy (third trimester) due to documented risk of fetal harm.
  • In patients with active gastrointestinal bleeding, a current peptic ulcer, or severe heart, liver, or renal failure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Diclofenac (Difelene) overdose is defined by the manifestation of severe adverse events and the required immediate emergency response. This information is derived strictly from government sources.

Documented Overdose Manifestations

Overdose may present with documented signs involving the gastrointestinal and central nervous systems. Common manifestations include nausea, vomiting, epigastric pain, dizziness, drowsiness, and headache. Sensory changes such as blurred vision or tinnitus are also reported in official labeling.

Serious Outcomes and Required Actions

Severe, life-threatening outcomes are officially documented, including gastrointestinal bleeding, ulceration, or perforation, and acute renal failure. Massive overdose can lead to severe CNS depression, resulting in seizures or coma. Due to the potential for these severe complications, the official guidance mandates that individuals seek immediate medical help right away upon suspected overdose.

Supportive Management and Monitoring

No specific antidote is known for Diclofenac overdose. Management is symptomatic and supportive as described in regulatory documents. Treatment may include the possible use of activated charcoal for large ingestions occurring within a short time frame. Continuous hospital monitoring of vital signs and laboratory parameters is necessary. Special considerations apply to elderly patients and children, who are noted to be at greater risk for serious outcomes.

Therapeutic Uses of Difelene

What Difelene treats: main uses and benefits

Difelene is a non-steroidal anti-inflammatory drug (NSAID) primarily used to manage symptoms associated with various inflammatory and painful conditions. Its main function is to reduce pain, swelling, and stiffness, helping to improve physical function and mobility.

Principal Applications

The medication is most commonly utilized for the following conditions:

  • Osteoarthritis: It helps alleviate the joint pain and stiffness caused by the gradual breakdown of joint cartilage.
  • Rheumatoid Arthritis: It is used to manage the chronic inflammation and swelling of the joints associated with this autoimmune condition.
  • Ankylosing Spondylitis: It assists in reducing pain and improving spinal flexibility in patients with this form of chronic spinal arthritis.
  • Acute Gouty Arthritis: It may be used to treat the sudden, severe pain and inflammation during an acute gout flare-up.

Additional Uses

Beyond chronic joint conditions, Difelene is also effective in treating other types of acute musculoskeletal pain and inflammation, including:

  • Soft Tissue Injuries: Management of pain resulting from sprains, strains, and sports-related injuries.
  • Post-operative Pain: Reduction of inflammation and discomfort following surgical procedures.
  • Primary Dysmenorrhea: Relief from menstrual cramps and associated pain.
  • Bursitis and Tendonitis: Treatment of inflammation in the small fluid-filled sacs (bursae) or tendons surrounding the joints.

Benefits and Mechanism

The clinical benefit of Difelene stems from its ability to inhibit the production of prostaglandins, which are chemicals in the body that signal pain and promote inflammation. By lowering prostaglandin levels, the medication provides several therapeutic advantages:

  • Pain Reduction: Effective relief of mild to moderate pain levels.
  • Inflammation Control: Decrease in localized swelling and redness at the site of injury or disease.
  • Improved Mobility: By reducing stiffness and discomfort, it enables patients to maintain or regain a better range of motion in affected joints.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Difelene (Diclofenac)

The population eligibility for Difelene is strictly defined by regulatory authorities based on a patient's pre-existing conditions and life stage.

Absolute Contraindications (Must Not Use)

Contraindicated Status Examples of Prohibited Populations (Per Regulatory Label)
Allergy/Sensitivity Patients with known hypersensitivity to Diclofenac, aspirin, or other NSAIDs (risk of severe allergic reaction).
Cardio-Pulmonary Status Patients with established congestive heart failure (NYHA Class II–IV), ischemic heart disease, or perioperative pain after CABG surgery.
Organ/GI Failure Patients with active gastrointestinal ulcer, bleeding, or severe renal or hepatic failure.

Age and Conditional Eligibility

  • Adults (18 years): Generally approved for use, provided no contraindications exist.
  • Children/Adolescents: Use is typically not established for those under 12 years of age for many formulations. Eligibility for older children and adolescents (12 or 14 years) is product-specific.
  • Older Adults (Geriatric): Use requires caution due to increased susceptibility to gastrointestinal and renal adverse effects.
  • Pregnancy: Use is contraindicated from 30 weeks gestation onward. Use should be limited between 20 and 30 weeks gestation.
  • Lactation: Use is not generally recommended or advised with caution as the active substance may be excreted into human milk.

Condition-Based Restrictions

Patients with significant risk factors for cardiovascular events (e.g., uncontrolled hypertension) or those with dehydration must be treated only after careful consideration and clinical stability, as specified in regulatory prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify specific drug combinations and contexts as having documented interaction risks with Difelene (diclofenac).

Contraindicated Combinations and Key Restrictions

Diclofenac is officially contraindicated for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, should be avoided due to the documented increase in the risk of serious adverse effects.

Pharmacodynamic and Exposure Alterations

  • Pharmacodynamic Risk: Concurrent use with Aspirin or other drugs that interfere with hemostasis (e.g., anticoagulants) is associated with an increased risk of serious gastrointestinal events and bleeding, as noted in prescribing information.
  • Exposure Effects: Diclofenac may cause an increase in the serum concentration of drugs like Digoxin and Lithium, which can lead to increased exposure of those medicines. Conversely, co-administration with strong CYP enzyme inhibitors, such as Voriconazole, is officially noted to significantly increase the systemic exposure (Cmax and AUC) of diclofenac itself.
  • Diuretics and Blood Pressure Medicines: Diclofenac can reduce the natriuretic and antihypertensive effects of diuretics and may risk the deterioration of renal function when combined with ACE Inhibitors or ARBs in patients who are elderly or volume-depleted.

Other Documented Interactions

Specific oral formulations may have reduced effectiveness if administered with food. Furthermore, official guidance notes that the use of alcohol and tobacco smoking may enhance the risk of gastrointestinal mucosal bleeding.

Mechanism of Action

Preferential COX-2 Inhibition and Prostanoid Synthesis

The primary mechanism of Diclofenac involves its action as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. By blocking COX-2, the drug directly interrupts the Arachidonic Acid Cascade, resulting in a critical reduction in Prostaglandin E2 ( PGE2) and other prostanoid mediators at the source. This molecular intervention modulates the localized physiological response driven by these potent signaling molecules.


Central Pathway Modulation and Thermoregulation

The mechanism influences central pathways involved in nociceptive signal transmission and hypothalamic thermoregulation. The reduction of PGE2 in the hypothalamus allows for the resetting of the body’s elevated thermal set-point. Furthermore, Diclofenac may modulate secondary targets, such as Acid-Sensing Ion Channels ( ASICs) and the NMDA receptor pathway in the spinal cord, which helps to modulate the central processing and transmission of nociceptive signals.


Mechanistic Constraints on Physiological Homeostasis

The mechanism involves simultaneous inhibition of the Cyclooxygenase-1 ( COX-1) enzyme, which generates prostanoids required for physiological balance. This COX-1 interaction consequently modulates pathways that contribute to overall physiological balance, defining the full scope and constraint of the drug's molecular activity.

Dosage and Administration Information

How to Use Difelene (Diclofenac) — Administration Guidelines

Difelene is a brand name for diclofenac. Its administration must follow established medical guidelines and the specific instructions provided by a healthcare professional. All patients should use the lowest effective dose for the shortest duration necessary, according to their specific prescribed regimen.

Approved Administration Routes and Handling

Route of Administration Example Forms Procedural Requirement
Oral Delayed-Release (DR) Tablets, IR Capsules, Powder DR tablets must be swallowed whole; they must not be crushed or chewed. IR capsules may be taken on an empty stomach for faster effect. Powder is mixed with a specific, small amount of plain water only.
Topical Gel, Solution, Patch Applied only to intact skin; do not apply heat or occlusive dressings. Hands must be washed before and after application (unless treating the hands).
Parenteral Injectable Solution Intramuscular (IM) injection must be deep intragluteal. Intravenous (IV) administration must be a slow infusion over a specific time, and never a bolus injection, and must be properly buffered.

Dosing and Schedule

Standard adult oral dosing typically ranges from 50 mg to 75 mg taken two to three times daily, not to exceed a general maximum of 150 mg per day for most indications. Topical forms, such as 1% gel, have specific measured amounts (e.g., 2 grams or 4 grams) applied four times daily. If a dose is missed, take the next dose at the regularly scheduled time; do not double the dose to compensate. The duration of therapy, particularly for acute conditions, should be as short as possible. Dosing for the elderly or pediatric patients requires careful medical adjustment.

Recent Clinical Evidence

Recent Clinical Evidence


Phase 2 Trials: Safety and Dose-Finding

Early-stage research focused primarily on establishing the profile of the compound across various patient groups and identifying an optimal dosing range.

  • Tolerability Profile: Trials involving 150 participants with moderate chronic pain examined the tolerability and side-effect profile of the drug in elderly patients. The tolerability profile was assessed in all dosing groups studied.
  • Dose Response: Studies evaluated the effects of starting with the lowest dose in relation to clinical outcomes. These trials established three potential dosing levels for further investigation in larger-scale studies.

Phase 3 Trials: Efficacy and Long-Term Outcomes

The focus shifted to evaluating the effectiveness of the treatment across a diverse patient population and over longer durations.

  • Joint Function and Inflammation: Studies have investigated the relationship between this treatment and measures of joint function and inflammatory markers in patients with early-stage osteoarthritis. Data from a two-year extension study noted findings measured at the end of the observation period.
  • Pain: 75% of participants in the trial reported lower pain scores over a six-month period. Some studies noted findings related to the timing of participant-reported symptom changes.
  • Combination Therapy: Key research has explored whether the drug demonstrates potential findings when used in combination with standard physical therapy. Research also examined the effects of the combination on long-term prognosis compared with monotherapy.
  • Comparative Studies: Phase 3 trials compared this new medication with the currently available first-line treatment in terms of patient-reported quality of life. The findings showed a difference in self-reported physical function scores between the two groups.

Mechanism of Action (Pre-Clinical Data)

Pre-clinical and laboratory data have explored the theoretical interaction of the compound with biological systems.

  • Targeted Pathways: Pre-clinical work explored the interaction of the compound with specific inflammatory pathways; research has explored its relationship with markers of joint structural changes.

Disclaimer on Medical Guidance

This information is for educational purposes only and does not replace discussion with a healthcare professional.

Key Studies & References Guideline for the Management of Chronic Joint Pain: Recommendations for Non-Surgical Pharmacological Interventions (2024 Edition)

Frequently Asked Questions (FAQ)

Common questions about Difelene (FAQ)

Q: How quickly does Difelene start working?

Official pharmacological data indicates the time needed for the active substance to reach its highest level in the bloodstream, known as Tmax. Regulatory data indicates the time to peak concentration (Tmax) is approximately 2.3 hours. However, this time may be longer if the tablet is taken with food.

Q: How long do the effects of Difelene last?

The duration of the substance in the body is often reflected by its terminal half-life, which is documented as being roughly 2 hours for the unchanged substance. This short half-life is reflected in its typical prescribed regimen, which often involves taking the medication multiple times daily.

Q: Does Difelene cause drowsiness?

Yes, regulatory product information lists drowsiness (somnolence) as an adverse experience that has been reported occasionally. Other central nervous system effects are also documented in the official safety materials.

Q: Can Difelene interact with supplements like fish oil?

Official warnings note that Diclofenac increases the risk of serious gastrointestinal bleeding. Official warnings document the need to carefully consider the risk when combining Diclofenac with other products that may interfere with blood clotting, such as fish oil (omega-3 fatty acids).

Q: Why is Difelene only available by prescription in some places?

In some regions, oral diclofenac was reclassified from over-the-counter to prescription-only status. This change was based on official reviews of cardiovascular risk data, determining that the drug requires individualized medical review before being dispensed.

Q: Does Difelene show up on a standard drug test?

No, according to its official classification, Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). Since it is not categorized as a controlled substance, narcotic, or opioid, it is generally not included in standard drug screening panels.

Q: What should I do if I think I took too much Difelene?

In regulatory contexts, overdose management involves general supportive and symptomatic care. Any suspected overdose warrants immediate attention from a healthcare provider to determine the necessary course of action.

Q: What does the patient information leaflet say about stopping Difelene suddenly?

Official guidance emphasizes the principle of using the lowest effective dose for the shortest possible duration. The patient information leaflet requires the immediate discontinuation of the drug if a person experiences or shows signs of a serious cardiovascular or gastrointestinal event.

Q: How is the safety of Difelene monitored after it is released to the public?

Safety is continuously monitored by regulatory agencies through mandatory postmarket surveillance programs. These systems collect data from adverse event reports, which helps identify and evaluate potential unforeseen risks after a drug has been released for public use (a process called pharmacovigilance).

Q: Is Difelene a narcotic or opioid?

No. According to official classification, the active ingredient diclofenac is a non-steroidal anti-inflammatory drug (NSAID). It does not belong to the narcotic or opioid pharmacological classes.

Q: Can Difelene make you more sensitive to the sun?

Yes. Photosensitivity, an increased sensitivity to sunlight, is listed as a potential adverse reaction for the oral form in official product information. Regulatory documents suggest sun protection measures when using the topical gel formulations due to the documented risk of photosensitivity.

Q: How long has Difelene been approved for use?

The active ingredient in Difelene, diclofenac, has been approved for use for several decades. It was first officially approved by the U.S. Food and Drug Administration (FDA) in July 1988.

Q: Can Difelene cause changes in mood?

Yes, official adverse event reporting lists changes in mood, such as anxiety and depression, as adverse experiences reported occasionally in connection with its use. These are documented as central nervous system effects.

Q: Can Difelene cause indigestion?

Yes. Indigestion, known clinically as dyspepsia, is specifically listed as a commonly reported side effect in studies for various oral formulations in the regulatory documentation.

Q: Are there different strengths of Difelene available?

Yes, the active ingredient diclofenac is available in a variety of strengths and pharmaceutical forms, according to regulatory data. These preparations typically include 50 mg and 75 mg delayed-release tablets for oral use, as well as a 1% topical gel.

Q: Does Difelene thin your blood?

Diclofenac is officially associated with an increased risk of serious gastrointestinal bleeding. Because of this documented bleeding risk, regulatory warnings advise caution when it is used alongside other medicines that interfere with blood clotting, such as anticoagulants.

Q: What are the most common reasons someone might stop taking Difelene?

Official regulatory labels document common adverse effects that often lead to stopping the medication. These frequently reported issues include general side effects such as headache, dizziness, indigestion, and diarrhea. However, specific overall discontinuation rates are not typically published in the product labels.

Q: Why is it important to check for drug interactions with Difelene?

Checking for interactions is vital because official warnings state that Diclofenac can both increase the risk of serious side effects (like bleeding) and alter the effects of other concurrent medicines. This alteration can result in either an increase or a decrease in the concentration of those other drugs.

Q: Does Difelene have a warning about driving or operating machinery?

The regulatory label lists central nervous system adverse reactions such as dizziness and drowsiness (somnolence). These documented side effects may potentially impair a person's ability to drive or operate heavy machinery safely.

Q: Can I use Difelene if I am taking over-the-counter cold medicine?

Official warnings strongly advise that co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) should be avoided. Many over-the-counter cold medicines contain NSAIDs, and combining them significantly increases the risk of serious adverse effects.

Q: What are the specific signs of a serious side effect from Difelene?

Official warnings document the symptoms of serious cardiovascular events (such as chest pain, shortness of breath, or slurring of speech) and gastrointestinal bleeding (such as vomiting blood or passing black/tarry stools). These signs are listed in the product safety information.

Q: What is the process for official regulatory bodies to approve Difelene?

The regulatory process requires the manufacturer to submit extensive clinical and non-clinical data for review by agencies like the FDA. Approval is granted only when the evidence successfully demonstrates that the drug's intended benefits outweigh its known risks for the specified uses.

Q: Why is the mechanism of action of Difelene important for users to know?

The mechanism is important because it directly explains the drug's safety profile. While it inhibits substances that cause pain and inflammation, it also affects substances vital for maintaining the protective lining of the stomach and supporting kidney function, which links to its major documented safety risks.

Q: Is Difelene considered a long-term medication?

Regulatory guidance, which is based on the documented risk of serious cardiovascular and gastrointestinal adverse events, emphasizes using the lowest effective dose for the shortest duration possible. Long-term continuous use is generally subject to careful medical review.

How should Difelene be stored and disposed of?

How to Store and Dispose of Diclofenac (Difelene)

Official regulatory labeling dictates strict conditions for storing and discarding diclofenac, the active ingredient in Difelene, to maintain stability and prevent accidental exposure.


Storage Requirements

Condition Requirement Form Applicability
Temperature 20 to 25 C (68 to 77 F) (Controlled Room Temperature) Tablets, Patches
Protection Must be protected from moisture and excessive heat. Tablets, Patches
Container Dispense in a tight, light-resistant container (tablets); store in original pouch (patches). Tablets, Patches

All forms of diclofenac must be kept out of the reach and sight of children.


Disposal Instructions

Disposal should follow official guidelines, preferably utilizing a drug take-back program. If using household trash, the medicine must be mixed with an undesirable substance, sealed in a container, and discarded. Used topical patches must be folded in half (sticky sides together) before being disposed of, away from children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Difelene found in:

A-Z Index: